Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - teriflunomide, quantity: 14 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; microcrystalline cellulose; hyprolose; maize starch; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; purified talc; indigo carmine aluminium lake - aubagio is indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. jadenu is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. jadenu is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. jadenu is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. jadenu is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. jadenu is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. jadenu is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - teriflunomide, quantity: 14 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; hyprolose; colloidal anhydrous silica; lactose monohydrate; maize starch; titanium dioxide; macrogol 8000; hypromellose; purified talc; indigo carmine aluminium lake - teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - teriflunomide, quantity: 14 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; maize starch; microcrystalline cellulose; hyprolose; sodium starch glycollate type a; titanium dioxide; macrogol 8000; hypromellose; purified talc; indigo carmine aluminium lake - teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hyprolose; colloidal anhydrous silica; crospovidone; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin; indigo carmine aluminium lake - lacosam tablets are indicated as: ? monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; crospovidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; lecithin; indigo carmine aluminium lake - lacosam tablets are indicated as: ? monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; hyprolose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; indigo carmine aluminium lake - lacosamide sandoz (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.,paediatric patents weighing less than 50 kg should not receive lacosamide sandoz film-coated tablets. paediatric patients weighing less than 50 kg should be accurately dosed on a mg/kg basis with other lacosamide products.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: poloxamer; purified talc; titanium dioxide; indigo carmine aluminium lake; hypromellose; magnesium stearate; colloidal anhydrous silica; povidone; macrogol 4000; microcrystalline cellulose; crospovidone - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox-teva is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,deferasirox-teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older